Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

Patients may not be able to tolerate recommended dose of cabozantinib

A recent study published on Oncology this month suggests that renal cell carcinoma (RCC) patients may not be able to tolerate the FDA-approved dose of cabozantinib, which was determined from the METEOR and CABOSUN clinical trials. In the current trial, a median daily dose of 33.2 mg was less than that administered in the METEOR […]

read more

Alternative sunitinib dosing schedule

A recent study carried out by a Japanese research team and published in the International Journal of Clinical Oncology has shown that an alternative “weekday-on and weekend-off regimen” of sunitinib administration for metastatic renal cell carcinoma (RCC) may improve relative dose intensity compared with the conventional 4 weeks on sunitinib, 2 weeks off schedule. The study […]

read more

Alternative 2 weeks on/1 week off dosing schedule for sunitinib

The results from a phase 2 study looking at the safety and efficacy of a 2 weeks on/1 week off dosing schedule for sunitinib show that severe (grade 3) toxicity is not decreased in patients with metastatic renal cell carcinoma (RCC). However, the schedule may improve other clinical outcomes, such as drug compliance, efficacy, and […]

read more

European Medicines Agency approves 4-week dosing schedule for nivolumab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a four-week dosing schedule for nivolumab for patients with advanced kidney cancer that has been previously treated. The dosing schedule will involve 480 mg nivolumab infused over 60 minutes. The CHMP also recommended approval of a […]

read more

Alternative sunitinib dosing schedule for the treatment of kidney cancer improves adverse events

Recently, the results of several studies have demonstrated that a 2 weeks on treatment, 1 week off treatment (2/1) dosing schedule for sunitinib improves adverse events, without reducing efficacy, in patients with metastatic renal cell carcinoma (RCC). Read a review article here and an article presenting real world evidence with a 2/1 dosing schedule for sunitinib […]

read more
Showing all 7 results
  TOP